Parvoduk

Lapsed

This medicine's authorisation has lapsed

live attenuated Muscovy duck parvovirus

Overview

The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Parvoduk : EPAR - Summary for the public

Reference Number: EMA/87390/2014

Product information

Parvoduk : EPAR - Product Information

Parvoduk : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Parvoduk
• Active substance:
  live attenuated Muscovy duck parvovirus
• International non-proprietary name (INN) or common name:
  live attenuated Muscovy duck parvovirus
• Species:
  Ducks
• Anatomical therapeutic chemical veterinary (ATCvet) code:
  QI01BD03

Pharmacotherapeutic group

• duck parvovirus
• Live viral vaccines
• Immunologicals for aves

Therapeutic indication

Active immunisation of ducks to prevent mortality¹ and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.

---

¹In absence of maternally derived antibodies.

Authorisation details

• EMA product number:
  EMEA/V/C/002740
• Marketing authorisation holder:
  Merial

  29 Avenue Tony Garnier; 69007 Lyon; France

• Marketing authorisation issued:
  11/04/2014
• Lapse of marketing authorisation:
  01/04/2019
• Revision:
  2

Assessment history

Changes since initial authorisation of medicine

Parvoduk : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Parvoduk : EPAR - Public assessment report

Adopted Reference Number: EMA/103539/2014

CVMP summary of positive opinion for Parvoduk

Adopted Reference Number: EMA/CVMP/60159/2014